BioCentury
ARTICLE | Financial News

Follow-on roundup

January 24, 2018 10:56 PM UTC

At least six companies priced follow-ons, raising more than $600 million total.

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) raised $250 million on Tuesday through the sale of 4.4 million shares at $57 in a bumped-up follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Goldman Sachs and Cowen. The price is a 7% premium to Ultragenyx's close of $53.39 on Monday, when it proposed after market hours to raise $175 million. ...